This is an aggregated industry headline. Read the full story at FiercePharma →
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
By FiercePharma
· Apr 30, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
dealsformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
DealsBriefing
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
DealsFierceBiotech ↗
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…